Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain scans reveal hidden damage in glaucoma patients

NCT ID NCT01621841

First seen Jun 13, 2026 · Last updated Jun 20, 2026 · Updated 1 time

Summary

This study uses a powerful 3-Tesla MRI to compare the visual pathways in the brains of 114 people with glaucoma against healthy volunteers of the same age and sex. The goal is to see if glaucoma causes damage beyond the eye, in the brain's visual processing areas. Researchers hope this will improve understanding of the disease and its links to other neurodegenerative conditions like Alzheimer's.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLAUCOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Service d'ophtalmologie Hôpital Pellegrin

    CHU de Bordeaux, Bordeaux, 33000, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors better understand how glaucoma affects the brain's visual pathways, potentially leading to earlier detection or new treatment targets.

What could go wrong

This is an observational imaging study, not a treatment trial. It may not directly lead to new therapies, and the findings might not apply to all glaucoma patients.

Conditions

The condition(s) this trial relates to.

Glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.